Brooklyn ImmunoTherapeutics (NYSE:BTX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Thursday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 0.6 %

Brooklyn ImmunoTherapeutics stock opened at $1.81 on Thursday. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10. The stock’s 50 day simple moving average is $1.90 and its two-hundred day simple moving average is $1.97. The firm has a market cap of $106.48 million, a PE ratio of -0.80 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.